Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

Am J Hematol. 2020 Sep;95(9):E225-E228. doi: 10.1002/ajh.25854. Epub 2020 May 23.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B / genetics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Decitabine / administration & dosage
  • Female
  • Gemtuzumab / administration & dosage
  • Hematologic Neoplasms* / drug therapy
  • Hematologic Neoplasms* / genetics
  • Hematologic Neoplasms* / mortality
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / mortality
  • Male
  • Neoplasm Proteins / genetics*
  • Polymorphism, Single Nucleotide*
  • Sialic Acid Binding Ig-like Lectin 3 / genetics*

Substances

  • ABCB1 protein, human
  • ATP Binding Cassette Transporter, Subfamily B
  • CD33 protein, human
  • Neoplasm Proteins
  • Sialic Acid Binding Ig-like Lectin 3
  • Decitabine
  • Gemtuzumab